Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results
Compass Therapeutics says results from its Phase 2/3 COMPANION-002 study of tovecimig were published in the Journal of Clinical Oncology and presented orally at ESMO 2026.
Related stories
Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing
Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company
M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC
Microsoft Says Consumer Products Services Recovered
Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery.
M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC
Microsoft restores consumer product services after outage
Microsoft said its consumer product services have been restored; other services are not included in the update.
M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC
Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption
Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider.
M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC
Tesla sells Cybercab to first private customers
Reuters reports Tesla is offering its Cybercab to its first private customers.
M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC
Microsoft says affected services fully recovered
L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC